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gastrointestinal malignancies, providing great diagnostic 
and treatment challenges. Clinicians should be aware of this 
rising problem. 
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 Introduction 
 The incidence of morbid obesity around the world has 
exponentially increased over the last decades  [1] . Accord-
ing to the WHO, in 2016, more than 1.9 billion adults were 
overweight of whom 600 million were obese. Worldwide 
2.8 million adults die each year following complications 
of obesity. In the fight against this epidemic, there has also 
been a steep increase in the number of bariatric surgical 
procedures, such as the sleeve gastrectomy ( Fig.  1 a) or 
gastric bypass ( Fig. 1 b). In morbidly obese patients, bar-
iatric surgery (BS) has been proven effective, not only in 
inducing weight loss, but also in resolving comorbidities 
such as diabetes mellitus and hypertension  [2] .
 Despite these clear advantages, BS also has some dis-
advantages, which can lead to major diagnostic and treat-
ment challenges. A frequently seen difficulty is, for ex-
ample, the regular need for vitamin supplementation be-
cause of malabsorption due to the bypassed and 
functionally shorter bowel. Furthermore, the interpreta-
tion of non-specific abdominal complaints becomes more 
difficult because of the great anatomical and physiologi-
cal changes. Moreover, in case of the more frequently en-
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 Abstract 
 Background/Aims: The incidence of morbid obesity has ex-
ponentially increased over the last decades. Bariatric surgery 
(BS) has been proven effective in inducing weight loss and 
resolving comorbidities associated with morbid obesity. 
However, BS can also lead to major diagnostic and treatment 
challenges in patients who develop upper gastrointestinal 
malignancies. It is important to create awareness of this ris-
ing problem.  Methods: Relevant literature was searched in 
PubMed.  Results: (Formerly) obese patients are more prone 
to develop upper gastrointestinal malignancies, mainly ad-
enocarcinoma of the distal esophagus, since obesity induces 
a chronic pro-inflammatory state due to endocrinological 
changes. When an upper gastrointestinal malignancy devel-
ops after BS, diagnosis is often delayed and challenging due 
to a different presentation of complaints and the altered 
anatomy following the earlier surgery. Also, a potentially cu-
rative resection is often more complex and reconstruction of 
the gastrointestinal continuity can be seriously hampered. 
 Conclusion: Due to the growing incidence of obesity and the 
increasing number of bariatric surgical procedures that are 
performed each year, it is expected that over the years to 
come, more post-BS patients will be diagnosed with upper 
 Received: November 9, 2016 
 Accepted: May 2, 2017 
 Published online: May 30, 2017 
 Win Hou Willy Tse 
 Erasmus MC University Medical Center 
 Department of Surgery,  ’s-Gravendijkwal 230 
NL–3015 CE Rotterdam (The Netherlands) 
 E-Mail w.tse   @   erasmusmc.nl 
© 2017 The Author(s)
Published by S. Karger AG, Basel 
 www.karger.com/dsu Th is article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modifi ed material requires written permission. Do
w
nl
oa
de
d 
by
: 
Er
as
m
us
 U
ni
v.
of
 R
ot
te
rd
am
 M
ed
ica
l L
ib
ra
ry
   
   
   
   
  
14
5.
5.
87
.1
58
 - 
6/
20
/2
01
7 
2:
51
:1
5 
PM
 Tse/Kroon/van Lanschot Dig Surg
DOI: 10.1159/000477267
2
countered bile duct stones, an endoscopic retrograde 
cholangiopancreatography becomes challenging  [3] . Fi-
nally, a less frequent, but particularly difficult problem 
arises when an upper gastrointestinal malignancy devel-
ops in these patients.
 In recent years, we have encountered an increase in 
post-BS patients presenting with upper gastrointestinal 
malignancies, confronting us with specific diagnostic and 
treatment challenges. Since BS is gaining more popularity 
each year, it is expected that the incidence of upper gastro-
intestinal malignancies in post-BS patients will show a 
steep increase as well. The specific challenges in diagnosis 
and treatment are described below, which clinicians will 
increasingly encounter in patients undergoing BS.
 Obesity and Its Carcinogenic Potential 
 Obesity induces a chronic pro-inflammatory state due to 
endocrine changes such as increased leptin and decreased 
adipokine release by adipocytes. Obesity is the driving force 
behind the metabolic syndrome, characterized by (central) 
obesity, insulin resistance, dyslipidemia, and hypertension 
 [1, 4–6] . This condition, also known as the “deadly quartet,” 
increases the risk of developing diabetes mellitus and car-
diovascular diseases, but also has a (systemic) carcinogenic 
effect resulting in an increased risk of developing various 
types of cancer, with esophageal adenocarcinoma leading 
this list  [3, 5, 6] . It has been shown that following BS, the risk 
of developing a variety of different tumors decreases again, 
further indicating that this relationship between obesity 
and carcinogenesis is indeed causal  [4] . However, the inci-
dence of malignancies in formerly obese patients after BS 
remains higher than in the general population.
 A body mass index of  ≥ 30 kg/m 2 quadruples the risk of 
developing an esophageal adenocarcinoma compared to 
those with body mass index <25 kg/m 2 . Although the ex-
act underlying mechanisms are not yet completely under-
stood, various hypotheses have been proposed. Besides 
the systemic pro-inflammatory carcinogenic effect of 
obesity, one of the local contributing factors is the in-
creased incidence of gastroesophageal reflux disease, 
leading to erosive esophagitis and ultimately Barrett 
esophagus, which is the premalignant condition for 
esophageal adenocarcinoma  [7] . This higher incidence of 
gastroesophageal reflux disease is probably caused by in-
creased intra-abdominal pressure, delayed gastric empty-
ing, decreased lower esophageal sphincter pressure, and 
increased transient lower esophageal sphincter relax-
ations, which have all been described in obese patients  [1] .
 Diagnostic Challenges 
 When an upper gastrointestinal malignancy develops 
after BS, diagnosis in these patients is often challenging. 
Vague symptoms, such as mild dysphagia and abdominal 
pain, are the first and often only signs  [3] . Particular diag-
nostic challenge occurs when a malignancy develops in the 
excluded gastric remnant following gastric bypass surgery. 
Initially the tumor remains silent and symptoms appear 
relatively late. Because of its late and altered presentation, 
diagnosis is often delayed resulting in a more advanced 
stage of tumor at the time of diagnosis. Double balloon ret-
rograde endoscopy performed via the Roux-en-Y anasto-
mosis or antegrade endoscopy via laparoscopically assisted 
gastrotomy may be necessary to reach the excluded gastric 
remnant in order to examine the gastric mucosa and to take 
biopsies for proper diagnosis  [3] . Due to the late presenta-
tion and difficult diagnostic work-up, less patients are eli-
gible for potentially curative surgery  [3] .
 Because of its malignant potential, the presence of 
 Barrett’s tissue in the distal esophagus is a contraindica-
tion to perform a gastric sleeve for weight loss. A recent 
review article by Braghetto and Csendes  [8] showed that 
a Roux-en-Y gastric bypass significantly improves reflux 
symptoms and can provide regression of intestinal meta-
plasia of the distal esophageal mucosa. In case of esopha-
geal or gastric cancer, curative options should be the pri-
mary goal. In order to diagnose Barrett’s tissue or possible 
malignancies prior to BS, the European guidelines for BS 
advise an endoscopy prior to considering BS  [9, 10] .
 Due to the increased malignant potential in (formerly) 
obese patients, lifelong frequent endoscopic monitoring 
is also advised  [9] . For structures that are assessed with 
difficulty by endoscopy, such as the gastric remnant fol-
lowing a gastric bypass, CT may be considered for moni-
toring, although this diagnostic modality is not as sensi-
tive to detect early lesions.
 Hampered Oncological Surgery 
 If stage permits, potentially curative resection is often 
challenging due to the altered anatomy following BS. In 
case of gastric cancer, oncological resection of the stomach 
and surrounding lymph nodes is technically more de-
manding. In patients with esophageal or esophago-gastric 
junctional cancer, reconstruction of gastrointestinal con-
tinuity is seriously hampered. In these cases, endoscopic 
resection of early tumor is the preferred option, however, 
in most cases this is not possible due to the more advanced 
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tumor stage at time of diagnosis because of the lack or 
vagueness of symptoms patients may experience after BS.
 After having undergone a previous sleeve gastrecto-
my ( Fig. 1 a), conventional reconstruction with a gastric 
tube (made of the greater curvature;  Fig. 1 c) is no longer 
possible. In such cases, a high intrathoracic esophago-
jejunostomy, if possible, and a colonic interposition are 
the reconstructive options, accompanied by higher per-
centages of postoperative complications, especially anas-
tomotic leakage. Vascularization may be compromised 
in case of high esophago-jejunostomy, while 4 anasto-
moses are to be created in the case of colonic interposi-
tion.
 In patients with a gastric bypass, the distal part of the 
stomach, duodenum, and first part of the small bowel are 
bypassed ( Fig. 1 b). In case of esophageal carcinoma, a gas-
tric tube can generally still be created from the gastric rem-
nant; however, it is also necessary to restore the normal 
anatomy of the jejuno-jejunostomy under these circum-
stances to prevent a short-bowel syndrome postoperatively.
 Conclusion 
 Despite the clear advantages of BS, clinicians are con-
fronted with serious diagnostic and treatment challenges 
when an upper gastrointestinal malignancy develops. 
Due to the increased carcinogenic potential in obese pa-
tients (especially for developing esophageal adenocarci-
noma), the ever growing incidence of obesity and the rap-
idly increasing number of BS procedures, it is expected 
that more post-BS patients will be diagnosed over time 
with upper gastrointestinal malignancies. These patients 
often suffer from more advanced tumors at the time of 
first presentation because of the altered anatomy, con-
fronting the clinicians with diagnostic challenges since 
the tumor is often difficult, if not impossible, to be reached 
by endoscopy. If tumor stage permits, surgery in these 
patients is more challenging. In case of gastric cancer, on-
cological resection is technically more complex, while in 
patients with esophageal and junctional cancer, recon-
struction of gastrointestinal continuity is more demand-
ing, requiring a high esophago-jejunal anastomosis or co-
lonic interposition, both at an increased risk of postop-
erative complications. Gastroenterologists and surgeons 
should be aware of this rising problem.
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 Fig. 1. Schematic representation of state following gastric sleeve resection (resected greater curvature is printed 
dimly,  a );  b state following gastric bypass surgery;  c state following gastric tube reconstruction. 
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